MX2020011586A - Virus vaccinia quimerico sintetico. - Google Patents

Virus vaccinia quimerico sintetico.

Info

Publication number
MX2020011586A
MX2020011586A MX2020011586A MX2020011586A MX2020011586A MX 2020011586 A MX2020011586 A MX 2020011586A MX 2020011586 A MX2020011586 A MX 2020011586A MX 2020011586 A MX2020011586 A MX 2020011586A MX 2020011586 A MX2020011586 A MX 2020011586A
Authority
MX
Mexico
Prior art keywords
synthetic chimeric
chimeric vaccinia
vaccinia virus
viruses
synthetic
Prior art date
Application number
MX2020011586A
Other languages
English (en)
Spanish (es)
Inventor
Seth Lederman
David Evans
Ryan Noyce
Original Assignee
David Evans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Evans filed Critical David Evans
Publication of MX2020011586A publication Critical patent/MX2020011586A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2020011586A 2018-05-02 2019-05-02 Virus vaccinia quimerico sintetico. MX2020011586A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862665973P 2018-05-02 2018-05-02
PCT/US2019/030486 WO2019213452A1 (en) 2018-05-02 2019-05-02 Synthetic chimeric vaccinia virus

Publications (1)

Publication Number Publication Date
MX2020011586A true MX2020011586A (es) 2020-12-07

Family

ID=68386164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011586A MX2020011586A (es) 2018-05-02 2019-05-02 Virus vaccinia quimerico sintetico.

Country Status (13)

Country Link
US (1) US12529036B2 (enExample)
EP (1) EP3788142A4 (enExample)
JP (3) JP2021522784A (enExample)
CN (2) CN112543806B (enExample)
AR (1) AR115069A1 (enExample)
AU (1) AU2019262149B2 (enExample)
BR (1) BR112020022181A2 (enExample)
CA (1) CA3099330A1 (enExample)
IL (1) IL278419B1 (enExample)
MX (1) MX2020011586A (enExample)
SG (1) SG11202010272PA (enExample)
TW (1) TW201946651A (enExample)
WO (1) WO2019213452A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319942A (en) 2016-11-02 2025-05-01 Evans David Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
CA3099330A1 (en) 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Synthetic chimeric vaccinia virus
CN115397998A (zh) * 2020-02-03 2022-11-25 希望之城 由天然或合成dna产生的基于痘病毒的载体及其用途
BR112022016992A2 (pt) * 2020-02-26 2022-10-25 Tonix Pharma Ltd Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス, インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
BR112023015467A2 (pt) 2021-02-02 2023-10-10 Geovax Inc Vetor viral de vaccinia ankara recombinante modificado, métodos para aumentar uma resposta imunológica a um antígeno alvo em um paciente e para prevenir, tratar ou induzir uma resposta imunológica contra um antígeno alvo, e, composição farmacêutica
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2023168286A1 (en) 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
CN116042656A (zh) * 2022-11-25 2023-05-02 中山大学附属第七医院(深圳) 一种猴痘病毒mRNA疫苗及其制备方法与用途
CN121992151A (zh) * 2026-02-03 2026-05-08 中国质量检验检测科学研究院 一种检测ⅰ、ⅱ型猴痘病毒分型的组合物及其分型检测试剂盒和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
CA2431349A1 (en) * 2002-06-06 2003-12-06 Xiao-Dan Yao Method of producing a recombinant virus
EP1668112A4 (en) 2003-06-20 2009-04-29 Protein Sciences Corp SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF
EP1678292A4 (en) 2003-09-18 2008-05-07 Univ Emory IMPROVED MVA VACCINES
WO2005103259A1 (en) 2004-04-26 2005-11-03 University Health Network Sars-cov nucleocapsid protein epitopes and uses thereof
WO2006022215A1 (ja) 2004-08-23 2006-03-02 The Japan Health Sciences Foundation SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用
CN101020055B (zh) 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
EP2697368B1 (en) * 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
CA2909225C (en) * 2013-04-10 2019-06-18 Tot Shanghai R&D Center Co., Ltd. Mutant vaccinia virus strains, uses thereof and method of producing the same
EP3045181B1 (en) 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
HK1248588A1 (zh) 2015-08-11 2018-10-19 Calidi Biotherapeutics, Inc. 用於癌症治疗中的天花疫苗
US11311615B2 (en) 2015-09-16 2022-04-26 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions
JP2019528753A (ja) 2016-09-21 2019-10-17 スティーブン エイチ. ソーン, 高移動度グループboxi突然変異体
IL319942A (en) * 2016-11-02 2025-05-01 Evans David Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof
ES2702618B2 (es) 2017-09-04 2019-10-31 Inst De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
CA3099330A1 (en) 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Synthetic chimeric vaccinia virus
US20210236619A1 (en) * 2018-05-02 2021-08-05 Tonix Pharma Holdings Limited Stem cells comprising synthetic chimeric vaccinia virus and methods of using them

Also Published As

Publication number Publication date
CA3099330A1 (en) 2019-11-07
AR115069A1 (es) 2020-11-25
WO2019213452A1 (en) 2019-11-07
JP2021522784A (ja) 2021-09-02
EP3788142A1 (en) 2021-03-10
CN112543806A (zh) 2021-03-23
IL278419B1 (en) 2026-07-01
CN121320271A (zh) 2026-01-13
US20210230560A1 (en) 2021-07-29
IL278419A (enExample) 2020-12-31
JP2025178289A (ja) 2025-12-05
SG11202010272PA (en) 2020-11-27
US12529036B2 (en) 2026-01-20
WO2019213452A9 (en) 2021-01-14
TW201946651A (zh) 2019-12-16
JP2024051112A (ja) 2024-04-10
AU2019262149A1 (en) 2020-11-12
CN112543806B (zh) 2025-06-06
AU2019262149B2 (en) 2025-09-11
EP3788142A4 (en) 2022-04-27
BR112020022181A2 (pt) 2021-02-09

Similar Documents

Publication Publication Date Title
ZA202403393B (en) Synthetic chimeric poxviruses
AU2015286723B2 (en) Influenza virus vaccines and uses thereof
GEAP202115353A (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
EP4349404A3 (en) Respiratory virus vaccines
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
MA39803A (fr) Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation
AR115069A1 (es) Virus vacuna quimérico sintético
MY191581A (en) Anti-pd-1 antibodies
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX2018005462A (es) Composiciones inmunogénicas de rsv quimérico y métodos de uso.
MX387421B (es) Producción de virus en huevos aviares.
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
PH12019501569A1 (en) Universal influenza vaccine compositions
EP3521409A3 (en) Perfume systems
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
WO2016119052A8 (en) Compositions and methods for enhancing oncolytic virus efficacy
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
MX2019007924A (es) Vacunas contra la influenza.
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
MX2022010827A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.